Stability seen in both long-term surgeon- and patient-reported outcomes data
THURSDAY, Sept. 3, 2020 (HealthDay News) — Prosthetic breast reconstruction outcomes do not deteriorate over time, according to a study published online in the September issue of Plastic and Reconstructive Surgery.
Akhil K. Seth, M.D., from the NorthShore University HealthSystem in Evanston, Illinois, and Peter G. Cordeiro, M.D., from the Memorial Sloan Kettering Cancer Center in New York City, examined long-term surgeon- and patient-reported outcomes following two-stage prosthetic breast reconstruction among 2,284 patients (3,489 breasts) treated from 1994 to 2016.
The researchers found that aesthetic scores and capsular contracture rates remained stable during the entire follow-up period. Bilateral and nonirradiated reconstructions consistently had the highest aesthetic scores, while unilateral irradiated breasts had the lowest. High rates of capsular contracture were seen consistently with irradiated breasts, although the extent of contracture improved over time in all patients. Over time, there was stability or improvement in patient-reported BREAST-Q scores in all patients. There was comparable long-term satisfaction with outcomes between irradiated and nonirradiated patients despite significant differences in satisfaction with their breasts.
“These results contradict the surgical dogma surrounding prosthetic breast reconstruction and therefore should be given significant consideration when counseling patients,” the authors write.
PET/MRI Offers Diagnostic, Prognostic Value in Pediatric Epilepsy
Dense Breast Notification Linked to Increase in Use of Supplemental Ultrasound
Less Intraoperative Crystalloid Fluid Not Tied to Worse Surgical Outcomes
Mammography Trials Yield Excess-Incidence Patterns Consistent With Low Overdiagnosis
Lower Breast, Cervical Cancer Screening Seen for Adults With Disabilities
Alcohol-Attributable Cancer Mortality Has Increased Significantly in the U.S.
Chemo-Free Combo of Four Targeted Therapies Shows Promise in Metastatic Breast Cancer
AMH Predicts Benefit of Chemo + Endocrine Therapy in Under 55s With Breast Cancer